Clin2
NCT07217860Likely a fitEnrolling by invitation

Long-term safety study of azetukalner for bipolar depression

Bipolar DepressionBipolar I DisorderBipolar DisorderBipolar II Disorder

Treatments studied

Part of Mental health clinical trials.

This study is looking at the long-term safety of azetukalner for people with bipolar I or II depression who have already completed a previous trial of this drug. It is an open-label study, meaning everyone will receive the active medication.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
400 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You must have completed a full treatment period in a previous study testing azetukalner for bipolar depression.
  • You must be willing to use effective birth control if you or your partner can become pregnant.
  • You cannot be pregnant, breastfeeding, or planning to become pregnant.
  • You cannot have any medical condition or ongoing side effect that would make the study unsafe for you.
  • You cannot be at significant risk of self-harm or suicidal behavior.
  • You cannot be planning to join another experimental drug or device trial during this study or within 28 days after it ends.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07172516Recruiting· Phase 3
Study of azetukalner vs placebo for bipolar depression

This trial tests whether the study drug azetukalner can help reduce depression symptoms in people with bipolar I or II disorder who are currently having a depressive episode. You would be randomly assigned to receive either the drug or a placebo (inactive pill) to see which works better.

Tucson, Arizona
NCT04987229Enrolling by invitation· Phase 3
Kid’s long-term safety follow-up for OLZ and SAM treatment

This study checks how safe a kid’s ongoing treatment is over a longer period. It is mainly for children who already finished a related study and may benefit from continuing the same medicines.

Dothan, Alabama
NCT05603104Recruiting· Phase 3
Medication intensification after first treatment failure in mood and psychosis

This Phase 3 study tests a stronger medication approach after your first current treatment hasn’t worked well enough. It targets people with schizophrenia, major depressive disorder, or bipolar depression who still have significant symptoms and life impact.

Ramat Gan
NCT07494305Recruiting· Phase 2
Testing a new drug for bipolar depression

This trial tests an investigational drug called LB-102 for people with bipolar I disorder who are currently experiencing a major depressive episode without psychosis. It aims to see if the drug is safe and effective for treating depression symptoms.

Bentonville, Arkansas
NCT05977023Recruiting· Phase 2
NMDA-targeted medicine to treat bipolar I depression

This Phase 2 study tests a medication that works on NMDA receptors to improve depression symptoms in people with bipolar I disorder. It may help if you’re currently in a bipolar depression episode and other mood treatments haven’t fully controlled it.

Taichung
NCT07263191Recruiting
Olanzapine study for bipolar disorder

This study looks at how well patients with bipolar disorder do while taking the medication olanzapine. You will continue your regular treatment, and answer questions about your experience.

Seongnam

Hear when a new Bipolar Depression trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.